What is Enzon Pharmaceuticals Financial Strength?
Enzon Pharmaceuticals has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Enzon Pharmaceuticals has no long-term debt (1).
As of today, Enzon Pharmaceuticals's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Enzon Pharmaceuticals's Financial Strength
For the Biotechnology subindustry, Enzon Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzon Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Enzon Pharmaceuticals's Financial Strength falls into.
Enzon Pharmaceuticals Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Enzon Pharmaceuticals's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-0.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil.
Enzon Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is
| Enzon Pharmaceuticals had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Enzon Pharmaceuticals Inc has no debt.
2. Debt to revenue ratio. The lower, the better.
Enzon Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Enzon Pharmaceuticals has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description
Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Executives
| Randolph C Read |
director |
C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022 |
| Jaffrey Adam Firestone |
director |
C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479 |
| Family Fund Couchman |
other: See Footnote 1 |
630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
| Jordan Bleznick |
director |
C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016 |
| Pearce Michael Cooper |
other: See explanation of responses |
213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517 |
| Harper Asset Management Llc |
other: See explanation of responses |
2945 S CENTER GREEN CT, G215, BOULDER CO 80301 |
| Brian James Harper |
other: See explanation of responses |
6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301 |
| Myrexis, Inc. |
other: See Footnote 1 |
600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020 |
| Xstelos Corp. |
other: See Footnote 1 |
630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
| Jonathan Couchman |
10 percent owner, other: See Footnote 1 |
630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
| Carl C Icahn |
10 percent owner |
C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160 |
| Richard L Feinstein |
officer: VP-Finance and PFO |
|
| Jonathan Christodoro |
director |
C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
| Kostas D Odysseas |
director |
660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
| Jennifer Isacoff Mcnealey |
director |
C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
Enzon Pharmaceuticals (Enzon Pharmaceuticals) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ENZN has been successfully added to your